人类表皮生长因子受体-2低表达型乳腺癌的临床分子特征及药物治疗研究进展  

Research progress on clinical molecular characteristics and drug therapy of breast cancer with low expression of human epidermal growth factor receptor-2

作　　者：程晓成 卫翀羿 隆建萍[1] 马秀芬[1] 毛红岩[1] 独晓燕[1] 曹廷宝 CHENG Xiaocheng;WEI Chongyi;LONG Jianping;MA Xiufen;MAO Hongyan;DU Xiaoyan;CAO Tingbao(Department of Breast and Thyroid Surgery,Gansu Provincial Maternity and Child Health Hospital/Gansu Province Central Hospital,Lanzhou 730000,Gansu Province,China)

机构地区：[1]甘肃省妇幼保健院/甘肃省中心医院乳腺与甲状腺外科,甘肃兰州730000

出　　处：《新乡医学院学报》2023年第6期574-578,共5页Journal of Xinxiang Medical University

摘　　要：乳腺癌作为女性常见的恶性肿瘤之一,其发病率一直居高不下。目前,乳腺癌被划分为luminal A型、luminal B型、人类表皮生长因子受体-2(HER-2)过表达型和三阴型4种分子亚型。2021年版《乳腺癌诊疗指南》提出了HER-2低表达这一概念。尽管HER-2低表达有了明确的定义,并且HER-2低表达型乳腺癌这类亚群似乎保留了独特的生物学特征,但其能否作为乳腺癌的另一个新亚型,现有的研究证据尚不太充足,需要进一步研究来验证。因此,本文就HER-2低表达型乳腺癌的临床分子特征、药物治疗策略、预后方面的研究新进展进行综述,以期为HER-2低表达型乳腺癌的后续研究提供理论依据。As one of the common malignant tumors in women,the incidence of breast cancer is always high.At present,breast cancer is divided into four molecular subtypes as luminal A,luminal B,human epidermal growth factor receptor-2(HER-2)overexpression and triple negative type.The concept of low expression of HER-2 was proposed in the 2021 guidelines for the diagnosis and treatment of breast cancer.Although the low expression of HER-2 has been clearly defined,and the breast cancer with low expression of HER-2 retains unique biological characteristics,but the existing research evidence is not enough to confirm whether it can be used as another new subtype of breast cancer.Therefore,this paper reviews the recent advances on clinical molecular characteristics and drug treatment strategies of breast cancer with low expression of HER-2 in order to provide a theoretical basis for the follow-up research of breast cancer with low expression of HER-2.

关 键 词：人类表皮生长因子受体-2 乳腺癌 药物治疗 

分 类 号：R730[医药卫生—肿瘤]